21st.BIO, a leading biotechnology company, has unveiled a groundbreaking pilot plant facility at its Danish headquarters. With the goal of assisting companies in scaling up their bioproduction processes, 21st.BIO combines cutting-edge technology with ample fermentation capacity to enable customers to reach large-scale production faster and more efficiently.
The need for pilot facilities in the biotech industry stems from the high cost and time-consuming nature of upscaling mistakes. Thomas Schmidt, co-founder and CEO of 21st.BIO, emphasizes the importance of getting the next step right for customers and highlights the company’s focus on increasing productivity as they move up in scale.
The pilot facility offers a range of services to facilitate and accelerate the transition from lab-scale fermentation to large-scale production. By leveraging their pilot construction and deep expertise, 21st.BIO can define crucial parameters and select the best equipment for optimal large-scale production of proteins through fermentation. This not only includes fermentation protocols but also assists customers in choosing the best contract manufacturing organization (CMO) for their specific project needs, mitigating the risk of costly failures.
Designed as a mini factory, the pilot facility replicates the equipment and processes found in large-scale biomanufacturing, albeit on a smaller scale. Thorvald Ullum, Chief Technology Officer at 21st.BIO, explains that customers work closely with experts in the pilot plant to test various process aspects and gain the skills and confidence necessary for their own large-scale production.
With over 3000 liters of fermentation capacity, the facility caters to various industries, ranging from nutrition and food to agriculture, biomaterials, and biopharma. It also fosters collaboration between 21st.BIO and customer teams, allowing for joint work on improving production strains and fermentation processes.
The grand opening of 21st.BIO’s pilot facility attracted prominent figures from the ingredient manufacturing industry and early-stage startups. The event also included an exclusive roundtable focused on the leadership of EU countries in the industrial scaling of biomanufacturing. Margrethe Vestager, Executive Vice President of the European Commission, underscored the sector’s potential to address key challenges and called for collaboration between policymakers and industry players to overcome funding obstacles and regulatory hurdles.
By facilitating large-scale protein production across the world, 21st.BIO aims to bridge the gap between groundbreaking molecular innovations and commercial success. With a focus on lowering production costs, the company provides advanced technology and know-how to industrial biotech innovators and global food giants. The introduction of the pilot facility marks the beginning of a journey towards building large-scale protein factories that prioritize cost-effectiveness and efficiency.
As Europe positions itself as a leader in the biotech sector, 21st.BIO is at the forefront of empowering companies to take science from the lab to the market. By combining their expertise with state-of-the-art facilities, they are revolutionizing bioproduction and supporting the global shift towards sustainable and locally produced bioproducts.
The 21st.BIO pilot facility introduced by the leading biotechnology company in Denmark aims to revolutionize bioproduction by providing cutting-edge technology and fermentation capacity to assist companies in scaling up their bioproduction processes. The need for pilot facilities in the biotech industry arises from the high costs and time-consuming nature of upscaling mistakes.
One key advantage of the pilot facility is that it allows customers to define crucial parameters and select the best equipment for large-scale production of proteins through fermentation. By testing various process aspects in the pilot plant, companies can gain the necessary skills and confidence for their own large-scale production.
The facility offers over 3000 liters of fermentation capacity, catering to various industries such as nutrition, food, agriculture, biomaterials, and biopharma. This provides an opportunity for collaboration between 21st.BIO and customer teams, allowing for joint work on improving production strains and fermentation processes.
The grand opening of the pilot facility attracted prominent figures from the ingredient manufacturing industry and early-stage startups. The event included a roundtable on the leadership of EU countries in industrial scaling of biomanufacturing. Margrethe Vestager, Executive Vice President of the European Commission, emphasized the potential of the sector to address key challenges and called for collaboration between policymakers and industry players.
As for current market trends, there is a growing demand for sustainable and locally produced bioproducts. With a focus on lowering production costs, 21st.BIO aims to bridge the gap between groundbreaking molecular innovations and commercial success. The company provides advanced technology and know-how to industrial biotech innovators and global food giants.
However, it is important to acknowledge some challenges and controversies associated with bioproduction. One key challenge is regulatory hurdles, which can delay the approval process and increase costs for companies. Collaborative efforts between policymakers and industry players, as highlighted by Margrethe Vestager, are necessary to overcome these obstacles.
Overall, the introduction of the pilot facility by 21st.BIO is a significant step towards advancing bioproduction and supporting the global shift towards sustainable and locally produced bioproducts.
For more information on the topic, you can visit the 21st.BIO website at 21st.BIO